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Autoantibodies to neutrophil cytoplasmic antigens (ANCA) do
not bind to polymorphonuclear neutrophils in blood.
Background. Autoantibodies to neutrophil cytoplasmic anti-
gens (ANCA), particularly to proteinase 3 (PR3), are found
in the majority of patients with systemic Wegener’s granu-
lomatosis. The autoantibodies are widely used as diagnostic
markers. Their role in the development and progression of the
disease, however, is still under investigation. The primary target
of ANCA, PR3, is located in the cytoplasm of polymorphonu-
clear neutrophils (PMN) or monocytes and is translocated to
the cell surface upon stimulation. In patients with Wegener’s
granulomatosis PR3 is up-regulated most prominently during
active disease. Despite the fact that both autoantibodies to PR3
and PMN expressing PR3 are present in patients with Wegener’s
granulomatosis, there is no evidence for binding of the autoan-
tibodies to PMN. The present study was designed to analyze
binding characteristics of autoantibodies to PR3 on PMN.
Methods and Results. PMN of patients with active Wegener’s
granulomatosis (N = 10) were tested for autoantibody bind-
ing. Despite high autoantibody titer and PR3 expression on
the PMN, no surface-bound IgG was found on PMN ex vivo.
When ANCA-containing plasma from patients was incubated
with isolated PMN, stimulated to express PR3, again no specific
binding of the autoantibody could be detected. Also keeping
the samples on ice did not allow surface detection of IgG, ruling
out degradation or internalization of the autoantibodies. Only
when purified IgG fractions were used, binding to PMN was
seen in 14 of 25 patients. Already 1% of plasma, however, was
sufficient to greatly reduce the IgG binding. Reduced binding
of the IgG fraction was also seen when a larger reaction volume
was used.
Conclusion. Our data indicate that autoantibodies to PR3
have a rather low affinity for surface-associated PR3 on PMN.
This, in turn, argues against the hypothesis that ANCA con-
tributes to the pathogenesis of the disease by stimulating viable
PMN in whole blood.
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culitis.
Received for publication October 16, 2003
and in revised form February 6, 2004, and March 12, 2004
Accepted for Publication April 1, 2004
C© 2004 by the International Society of Nephrology
According to the original description, Wegener’s gran-
ulomatosis is a chronic inflammatory disease char-
acterized by necrotizing granulomatous inflammation,
particularly of the respiratory tract, by systemic necro-
tizing vasculitis, and by glomerulonephritis (reviewed in
[1]). The etiology and pathogenesis of Wegener’s gran-
ulomatosis is not yet known. Association with bacterial
infections, environmental factors, or certain drugs have
been proposed, as have autoimmune phenomena [2–4].
The concurrence of autoantibodies to neutrophil cy-
toplasmic antigens (ANCA) with Wegener’s granulo-
matosis [5], and the identification of the major target
antigen, proteinase 3 (PR3) [6], lead to the hypothesis
that ANCA may activate the proinflammatory poten-
tial of polymorphonuclear neutrophils (PMN) [7–9]. That
PR3 is expressed on PMN of patients with active disease
is consistent with this hypothesis [10] as are reports on
the presence of activated PMN in the peripheral blood of
patients with active Wegener’s granulomatosis [11–14].
The potential for tissue destruction and propagation
of inflammatory reactions of inappropriately activated
PMN is well recognized [15, 16]. While activation due
to infection results normally in the emigration of PMN
into the infected sites, where they generate and release
their cytotoxic mediators, the activation in the microvas-
culature can cause damage to the vascular bed, includ-
ing enhanced permeability, endothelial cell damage, and
vasculitis. Moreover, due to de novo synthesis of cy-
tokines and surface receptors, the functional repertoire
of PMN expands during the inflammation (reviewed in
[15, 16]). While in Wegener’s granulomatosis a participa-
tion of PMN in vasculitis and also in glomerulonephritis
[17] is well established, the activating entities are not yet
identified.
ANCA appeared to be good candidates, because of
their association with active disease and because nu-
merous in vitro studies described the ability of ANCA,
and specifically of antibodies to PR3, to activate PMN
and monocytes. Release of proinflammatory mediators,
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including cytokines, oxygen radicals, prostanoids, and
nitric oxide, was described, as was priming for higher
responsiveness toward a secondary stimulus, and up-
regulation of activation-associated surface receptors
[18–24].
Because binding of ANCA to PMN is central for their
proposed role in Wegener’s granulomatosis, the present
study was designed to analyze the interaction of ANCA
with PR3-expressing PMN. Binding of other autoanti-
bodies to PMN, for example, to myeloperoxidase, elas-
tase, and lactoferrin was not addressed in this study,
nor were patients with vasculitis other than Wegener’s
granulomatosis.
METHODS
Patients
After approval by the Ethikkommission (Ethic com-
mittee) of the University Heidelberg Hospital and after
having obtained informed consent, blood was taken from
patients with Wegener’s granulomatosis. Wegener’s gran-
ulomatosis was defined as proposed by the Chapel Hill
conference [25] and diagnosed according to the ACR cri-
teria [26]. Disease activity was determined by the “Birm-
ingham Vasculitis Activity Score” (BVAS) [27]; ANCA
titers and PR3 titers were measured as reported else-
where [28, 29]. Ten patients with active disease (BVAS
>3) were included. From 64 patients with Wegener’s
granulomatosis, plasma samples (stored at −20◦C) were
used. All patients included in this study were negative for
other autoantibodies (e.g., to nuclear antigens, myeloper-
oxidase, elastase or lactoferrin, or for rheumatoid factor).
For comparison, whole blood, PMN, or plasma of healthy
donors were used.
Cytofluorometry
To reduce artifacts due to storage or handling, surface-
associated IgG and expression of PR3 were measured
in whole blood, gathered in heparinized tubes (Saarst-
edt, Nu¨mbrecht, Germany) within 1 hour after blood
withdrawal. A polyclonal antibody to PR3, raised in
rabbit (Elastin Products, Ownesville, MO, USA) (5 lL
per 100 lL blood) was used and antirabbit IgG
(from goat), fluorescein isocyanate (FITC)-conjugated
(Jackson ImmunoResearch, purchased from Dianova,
Hamburg, Germany), as was a monoclonal antibody to
PR3 (PeliCluster, purchased from Ho¨ltzel Diagnostika,
Ko¨ln, Germany) and a antimouse IgG-FITC (from goat)
(Jackson ImmunoResearch). Binding of ANCA (or IgG)
to PMN was measured by a FITC-labeled antibody to
human IgG (from goat), recognizing all IgG subclasses
(Jackson ImmunoResearch) and was measured as mean
fluorescence intensity (MFI). For comparison, antimouse
IgG FITC or antirabbit IgG FITC (also produced in goat)
(Jackson ImmunoResearch) were used.
PMN were identified by expression of CD66b, mono-
cytes using CD14 (Jackson ImmunoSearch); a gate was
set around the CD66b- or CD14-positive cells, respec-
tively, and 10,000 events were counted. Facscalibur was
used with Cellquest as software (Becton and Dickinson,
Heidelberg, Germany).
Experimental conditions to detect surface-associated
ANCA. Whole blood (300 lL) was incubated either on ice
or at room temperature with 1 to 10 lL of the antihuman
IgG FITC for 20 minutes in the presence of 0.1% sodium
azide to prevent internalization. Then the erythrocytes
were lyzed using lyzing solution (Becton and Dickinson).
The cells were resuspended in phosphate-buffered saline
(PBS) (0.01 mol/L pH 7.4, containing paraformaldehyde
1%) and were subjected to cytofluorometry. For compari-
son antibodies to either mouse or rabbit IgG were used, as
were untreated cells to control for the autofluorescence.
Of the isolated cells 1 × 105 to 1 × 106 were sus-
pended in 300 lL “FACS” buffer [PBS 0.01 mol/L, pH 7.4,
containing 1% bovine serum albumin (BSA) and 0.1%
sodium azide]. Plasma as source of ANCA was used undi-
luted (100 lL), as was plasma of healthy donors. Of the
IgG preparations (see below) 2 to 8 lg in a volume of
100 lL PBS was used, if not indicated differently. The
cells were incubated with ANCA or IgG, respectively, for
20 minutes at 4◦C or 22◦C, then washed twice in FACS
buffer, before adding the antihuman IgG FITC for an-
other 20 minutes. To account for interindividual differ-
ences, each plasma or IgG sample was tested with PMN
from three different donors. Since the results did not vary
considerably, only one of the three results is shown in the
figures or tables.
PMN isolation and induction of PR3 expression
PMN were isolated from heparinized blood by
PolymorphprepTM (Nycomed, Oslo, Norway) followed
by hypotonic lysis. This yielded 85% to 95% pure PMN.
To induce PR3 expression, PMN were suspended in
Hank’s buffered salt solution (HBSS), pH 7.2, consist-
ing in 10 mL 10 × Hank’s, 275 lL 1 mol/L Tris HCl, pH
7.25, 170 lL 1.1 mol/L CaCl2, 200 lL 0.4 mol/L MgSO4,
and 0.2 g glucose in 100 mL water) and incubated with
phorbol-myristate-acetate (PMA) (Sigma, Deisenhofen,
Germany), 1 lg/mL for 20 minutes at 37◦C. PR3 ex-
pression was measured by cytofluorometry as described
above. The polyclonal antibody (1 to 5 lL) and the mono-
clonal antibody to PR3 (1 to 2 lL) gave essentially similar
MFI when tested on activated PMN of the same donor.
Following preincubation with the polyclonal antibody for
15 minutes on ice, the binding of the monoclonal antibody
was inhibited and vice versa.
Preparation of IgG from whole plasma
Protein A sepharose CL-4B (Pharmacia Biotech, Upp-
sala, Sweden) was used and IgG was prepared according
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Table 1. Expression of proteinase 3 (PR3) and binding of autoantibodies to neutrophil cytoplasmic antigens (ANCA) to polymorphonuclear
neutrophils (PMN) of patients with Wegener’s granulomatosis and active disease, or to PMN of healthy donors
PR3 expression on PMN (detected by ANCA on PMN (detected by
a polyclonal antiserum generated in rabbit) antihuman IgG FITC)Patient Antibodies to
number ANCA titer PR3 in plasma % positivea PMN MFIa % positive PMN MFIa
1 320 >100% 96.7 34 2.6 88
2 640 >100% 43.4 43 3.7 78
3 320 >100% 51.6 49 8.7 94
4 160 53.6% 87.5 54 12.7 56
5 80 87.3% 34.6 21 4.5 80
6 80 24.7% 78.7 31 14.7 69
7 160 >100% 100 49 4.0 56
Mean ± SD 70.6 ± 26.7 40.4 ± 11.9 7.3 ± 4.8b 74.4 ± 14.8b
Healthy donors No data 22.1 ± 21.9 39.1 ± 13.0 14.9 ± 5.2 88.8 ± 12
(N = 10)
MFI is mean fluorescence intensity; FITC is fluorescence isothiocyanate.
a% positive PMN or MFI were determined by cytofluorometry from experiments similar to those shown in Fig.1 using the Cellquestprogram.
bThe mean values do not differ significantly between the patients and the donor group [tested by two-sided t test or analysis of variance (ANOVA)].
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Fig. 1. Determination of proteinase 3 (PR3)
expression on and binding of autoantibodies
to neutrophil cytoplasmic antigens (ANCA)
to polymorphonuclear neutrophils (PMN)
derived from a patient with Wegener’s gran-
ulomatosis. (A) PR3 was detected on PMN
in whole blood [patient 1, with active disease;
Birmingham Vasculitis Activity Score (BVAS
9)] by use of a polyclonal rabbit antibody to
PR3 and fluorescein isothiocyanate (FITC)-
labeled antirabbit IgG. The thin line shows
the control (rabbit IgG plus FITC-labeled
antirabbit IgG); the thick line anti-PR3. (B)
From the same blood sample, an aliquot was
incubated with antihuman IgG, FITC-labeled
(thick line); for comparison unlabeled cells
are shown (thin line). (C) Binding of the
antihuman IgG (thick line) to erythrocytes
in whole blood of a patient with “Coombs-
positive” autohemolytic anemia is shown (the
autoantibody was identified as anti-e Rhesus
antibody); the patient had severe anemia as
indicated by total hemoglobin 6.4 g/dL; lactate
dehydrogenase (LDH) 700 U/L; haptoglobin
<8 U/L. For comparison, antimouse IgG (pro-
duced in goat similarly to the antihuman IgG)
was used (thin line).
to the protocol given by the supplier. Of each patient
or of the healthy donors, respectively, 1 mL plasma was
used and incubated over night at 4◦C with constant shak-
ing. Following repeated washing, IgG was eluted with
500 lL 0.1 mol/L citric acid buffer, pH 3.0, dialyzed
against distilled water and finally against PBS. Protein
concentration was measured photometrically. The IgG
fraction of patients is termed “IgG-PR3-ANCA” in the
following. In concentrations of 0.1 to 1 lg/mL, positive
immunofluorescence with ethanol-fixed PMN was seen.
Statistics
Differences between mean values were calculated us-
ing t test for unpaired samples.
RESULTS
Expression of PR3 on PMN of patients with active
Wegener’s granulomatosis, but no evidence for
binding of ANCA
PMN of seven patients with active Wegener’s granulo-
matosis, ANCA titers ≥1:640 and autoantibodies to PR3,
were analyzed by cytofluorometry (Table 1). To avoid ar-
tifacts due to the purification procedures, analysis was
done in heparinzed whole blood. With a polyclonal an-
tibody to PR3, raised in rabbit, PR3 was found on PMN
of all the patients, and to a lesser extent on PMN of the
healthy donors (data derived from one patient are shown
in Fig. 1) (data of all patients and of the donors are sum-
marized in Table 1). PR3 expression was also seen on the
monocytes (data not shown).
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Table 2. Direct comparison of binding of antibodies to IgG a 4◦C or
22◦C
Binding of Binding of
antihuman IgG antimouse-IgGPatient ANCA
number titer 4◦C 22◦C 4◦C 22◦C
8 320 31.3a 34.5 20.9 22.3
9 320 33.9 24.2 25.7 15.4
10 80 19.0 45.9 17.5 18.7
Donors No 28.4 ± 14.4 31.3 ± 16.0 24.5 ± 12.9 21.3 ± 14.8
(N = 3) ANCA
ANCA is autoantibodies to neutrophil cytoplasmic antigens.
aMeasured as mean fluorescence.
Because of the simultaneous presence of PR3 on PMN
and autoantibodies to PR3 in the plasma, it was tested
next whether IgG was bound to the patients’ PMN. A
FITC-labeled antibody to human IgG, reacting with all
IgG subclasses was used and binding was compared to
blood samples without any antibody added (to account
for the autofluorescence), or to samples incubated with
FITC-labeled antbodies to either mouse IgG or rabbit
IgG in similar protein concentrations (Fig. 1). The mean
fluorescence obtained with antihuman IgG (MFI 74.4 ±
14.8) did not differ from that obtained with antimouse
IgG (66.9 ± 15.9) or antirabbit IgG (88.4 ± 25.0). More-
over, there was no difference in binding of antihuman IgG
FITC to PMN of patients with active disease compared
to PMN of healthy donors (Table 1). Of three additional
patients (patients 8 to 10) two blood samples were taken.
One was kept and processed on ice (4◦C), the other at
room temperature (22◦C). There was no difference in
antihuman IgG binding between the samples, indicating
that temperature had no effect on anti-IgG binding (data
summarized in Table 2).
That the antibody to human IgG was able to recog-
nize surface-bound IgG was tested by using blood of a
patients with “Coombs-positive” autoimmune hemolytic
anemia, where binding of the antihuman IgG occurred
to erythrocytes, but not of antimouse IgG (an example is
shown in Fig. 1C).
Thus, from these data, there is no evidence for bind-
ing of PR3-ANCA to PR3 expressing PMN derived
from the peripheral blood of patients with Wegener’s
granulomatosis.
Binding of PR3-ANCA to PMN of healthy donors
In another set of experiments, binding of PR3-ANCA
to PMN of healthy donors was tested. The PMN were
isolated from the peripheral blood and incubated with
PMA to induce PR3 expression. Depending on the indi-
vidual donor, PR3 expression was achieved on 70% to
100% of the PMN (mean 85 ± 10.2%, N = 5) as de-
termined by use of the rabbit antibody to PR3 or the
monoclonal antibody (an example is shown in Fig. 2A).
The PMN were incubated with plasma from patients with
Wegener’s granulomatosis and for comparison with
plasma of healthy donors. Binding of PR3-ANCA was
determined by a FITC-labeled antibody to human IgG
and measured as MFI. The MFI obtained with the in-
dividual plasma samples varied widely. In Fig. 2B, data
for 42 patients with ANCA titers ranging from 1:20 to
1:1280 are shown in relation to the mean fluorescence.
There was no correlation between the ANCA titer and
the MFI. Moreover, when compared as groups, the MFI
did not differ between plasma of patients with positive,
high ANCA titer (≥1:160; anti-PR3 >100%; N = 15), or
plasma of patients with Wegener’s granulomatosis in re-
mission and no ANCA (≤1: 20; no detectable anti-PR3;
N = 24), or plasma of healthy donors (N = 20) (Fig. 2C).
That MFI occurred independently of the ANCA titer
was also seen in follow-up studies. When plasma with
high ANCA titer (obtained when the disease was active)
was compared with plasma of the same patient taken after
remission and when the ANCA titer had declined, nearly
identical mean fluorescence was seen (data of one patient
are shown Fig. 2D) (data of five patients are summarized
in Table 3). Again, carrying out the binding assay on ice
did not yield ANCA-dependent binding (an example is
shown in Fig. 2D).
The data so far indicated that incubation of PMN with
plasma caused a minor increase in the MFI, which was
not dependent on the ANCA or more specifically, the
anti-PR3 titer. In line with this finding, a monoclonal an-
tibody to PR3 did not affect binding of ANCA-positive
plasma to PMN, while, as expected, binding to PMN of
the polyclonal rabbit anti-PR3 was inhibited by 40% to
50% (measured as reduction of MFI).
With essentially similar experiments, binding of ANCA
to isolated monocytes of healthy donors was tested.
Again, there was no evidence for a PR3-dependent bind-
ing (data not shown).
Binding of purified IgG-PR3-ANCA to PR3-expressing
PMN of healthy donors
From the plasma of 25 patients with high ANCA titer
(>1:640 and PR3 >100%), and from six donors, IgG was
prepared, and binding of the IgG fraction, in the follow-
ing termed IgG-PR3-ANCA, to PMA-treated PMN was
tested. For 14 of the 25 patient-derived IgG preparations
binding to PMN exceeding that of IgG obtained from
healthy donors was seen, when 2 to 8 lg protein were
used (Fig. 3).
Testing the specificity of binding did not yield entirely
conclusive results. Preincubation of PMN with the mon-
oclonal antibody to PR3 reduced binding of IgG-PR3-
ANCA (34 ± 17%), as did mouse IgG (18 ± 12%) (mean
of five experiments using IgG-PR3-ANCA derived from
different patients). With all IgG-PR3-ANCA, however,
inhibition by anti-PR3 was more pronounced, suggesting
that at least a part of the IgG binding was PR3-specific.
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Fig. 2. Binding of autoantibodies to neutrophil cytoplasmic antigens (ANCA) to proteinase 3 (PR3)-expressing polymorphonuclear neutrophils
(PMN) of healthy donors. (A) Incubation PMN of a healthy donor with PMA causes an up-regulation of PR3 on the surface (detected by antirabbit
PR3, thick line, the thin line shows binding of rabbit IgG). In this experiment 73% of the donor PMN acquired PR3. (B) Binding of ANCA-containing
plasma to PMN pretreated with PMA. The ANCA titer of the patient’s plasma, ranging from 1:20 to 1:1280 (N = 42) is plotted (y axis) against
the mean fluorescence (x axis) obtained after incubating PMN with the plasma. There is no correlation between the two values. (C) Binding of
ANCA-containing plasma or control plasma to PMN pretreated with PMA. Binding data from 15 patients with ANCA titer >160; PR3 >100%
(ANCA-positive) are summarized, as are data from 24 patients with ANCA <20 and anti-PR3 0 (ANCA-negative) and of 20 healthy donors. The
boxes contain 50% of the values. There was no statistically significant difference between the three groups. (D) Plasma with ANCA (titer 1:1280;
anti-PR3 >100%) was incubated with PMN at 4◦C or 22◦C (c and d), then secondary antibody [antihuman IgG-fluorescenin isothiocyanate (FITC)]
was added (thick line); the thin line shows binding of the secondary antibody alone. For comparison, plasma of the same patient, taken during
remission (ANCA titer 1:40; anti-PR3 11.3) was tested (a and b). The lower panel shows (e) the overlay of the histograms (a and c) and (f) of (b
and d), respectively (for clarity, the isotype controls are not shown on the overlay).
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Table 3. Binding to proteinase 3 (PR3)-expressing
polymorphonuclear neutrophils (PMN) of patient-derived plasma
compared with binding of plasma taken during acute disease, when
the autoantibodies to neutrophil cytoplasmic antigens (ANCA) titer
and anti-PR3 titers were high, with plasma taken of the same patient
in remission
ANCA on PMN mean
Patient number ANCA titer Anti-PR3 fluorescence intensity
330
Acute disease 160 >100% 401
Remission 20 28% 403
434
Acute disease 1240 >100% 489
Remission 40 11.3% 587
468
Acute remission 80 76% 467
Remission 0 0% 527
373
Acute remission 80 >100% 361
Remission 0 0% 496
326
Acute remission 160 34% 49.9
Remission 0 0% 81.5
0
12
0
Co
un
ts
100 101 102 103 104
IgG
M1
M2
0
10
20
30
40
50
60
70
80
90
100
Ig
G
 o
n 
PM
N,
 M
FI
ANCA-IgG IgG
Healthy donors
Fig. 3. Binding of IgG prepared from autoantibodies to neutrophil cy-
toplasmic antigens (ANCA)-containing plasma to polymorphonuclear
neutrophils (PMN). Of 25 patients with ANCA titer of 1:640 or higher
and proteinase 3 (PR3) titer >100% IgG was prepared. In concen-
trations of 4 lg/100 lL, IgG was added to phorbol-myristate-acetate
(PMA)-activated PMN (3 × 105/300 lL). (A) Data of patient 1. The
thick line represents binding of IgG-ANCA, the thin line donor IgG.
(B) Binding of IgG-ANCA [measured as mean fluorescence intensity
(MFI)] derived from 25 patients to donor PMN is shown, as is binding
of IgG prepared from plasma of healthy donors (N = 6).
The observation that binding of isolated IgG-PR3-
ANCA was seen while plasma failed to bind, despite high
reactivity with ethanol-fixated PMN, suggested that the
autoantibodies were of low affinity. Since direct deter-
mination of the affinity of polyclonal antibodies within
an IgG preparation is not possible, various experiments
were performed to indirectly get information on binding
characteristics of the ANCA.
In a first set of experiments, the effect of heat-
inactivated normal plasma on binding of IgG-PR3-
ANCA to PMN was tested. With plasma concentrations
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Fig. 4. Inhibition of IgG-autoantibodies to neutrophil cytoplasmic
antigens (ANCA) binding to polymorphonuclear neutrophils (PMN).
(A) IgG-ANCA was added to phorbol-myristate-acetate (PMA)-
activated PMN (2 lg IgG protein in a total volume of 200 lL) in the
absence (thin line) or presence of plasma (1% volume) (thick line)
(the IgG controls are shown as inserts). (B) A similar experiment with
anti-proteinase 3 (PR3) from rabbit. Here the two peaks coincide. (C)
Binding of 2 lg IgG-ANCA in a total volume 200 lL (thick line) or 1000
lL (thin line) is shown. (D) Binding of IgG-ANCA in a total reaction
volume of 1000 lL (thin line) is in the range of the IgG control (2 lg
IgG isolated from a healthy donor; thick line).
as low as 1%, the binding of IgG-PR3-ANCA was re-
duced by 20% to 50% (mean 33.7 ± 12, N = 12) (an
example is shown in Fig. 4). In the presence of higher
plasma concentrations (5% to 10%) binding was totally
inhibited. Also adding purified IgG or albumin (1 to 5 lg)
inhibited binding of IgG-PR3-ANCA as did increasing
the reaction volume. A doubling of the volume already
reduced binding by 50%, increasing the volume fivefold,
prevented binding entirely. Of note is that binding of the
polyclonal rabbit IgG was not inhibited by plasma, or
by increasing the reaction volume. Both sets of experi-
ments indicate that the IgG-PR3-ANCA binding is of low
affinity.
DISCUSSION
Since the detection of ANCA, the participation of
those antibodies in the development and the progression
of the disease has been investigated. Despite the facts
that ANCA are not unique for Wegener’s granulomato-
sis, that ANCA are not necessarily present in the ini-
tial phase of the disease or in localized disease, and that
there are patients with Wegener’s granulomatosis who
are constantly negative for ANCA [30–32], there is an
increasingly strong belief that Wegener’s granulomatosis
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is an autoimmune disease and that one of the underlying
molecular mechanisms is the activation in the microvas-
culature of living PMN by ANCA [2, 3, 7–9].
The data presented here argue against this hypothe-
sis, because binding of ANCA to its presumed target,
the PR3-expressing PMN, could not be demonstrated.
On peripheral blood PMN from patients with active We-
gener‘s granulomatosis and autoantibodies to PR3, no
surface-bound IgG could be detected, despite the fact
that PR3 was expressed and bound the heterologous
(rabbit) antibody. The most straightforward explanation
is that ANCA, in contrast to the heterologous antibody,
cannot bind to surface-associated PR3. The failure of
ANCA to bind to intact PMN could be confirmed by
in vitro experiments. When PMN of healthy donors,
stimulated to express PR3, were incubated with ANCA-
containing plasma of patients with Wegener’s granulo-
matosis, only a minor increase in MFI was seen when
FITC-labeled anti-IgG was added. This increase, how-
ever, was not dependent on the ANCA/anti-PR3 titer,
nor could it be inhibited by a monoclonal antibody to
PR3, the latter in contrast to binding of the polyclonal,
rabbit-derived antibodies to PR3. The most likely inter-
pretation is that the increase in fluoresecence was due to
binding of plasma IgG in an antigen-unspecific manner,
such as binding via its Fc portion to the Fc receptors on
PMN.
In contrast to plasma, IgG fractions prepared from the
ANCA-containing sera bound to PMN. For the majority
of patients the binding of IgG-ANCA exceeded that of
normal IgG, and could, at least in part, be inhibited by
antibodies to PR3. Binding, however, was inhibited by
plasma, by normal IgG or by albumin, and by increasing
the reaction volume. These findings are compatible with
low-affinity binding of PR3-ANCA.
Taken together, our data show that autoantibodies to
PR3 fail to bind to viable PMN expressing PR3 under in
vivo analogue conditions (i.e., in plasma), and that bind-
ing of the IgG-ANCA, if it occurred at all, was of low
affinity.
Why ANCA fail to bind to intact PMN as measured ex
vivo or when in whole blood, while binding to ethanol-
fixed PMN or to soluble PR3 [e.g., as it used for the
enzyme-linked immunosorbent assay (ELISA)] occurs is
under investigation. Various, not mutually exclusive, ex-
planations seem possible, including degradation of IgG
by the surface-associated PR3, internalization of the im-
mune complex, or blocking of the binding by plasma
factors. We think that these explanations are unlikely
because keeping the samples on ice, which should pre-
vent degradation, did not allow surface detection of IgG.
Moreover, degradation should be most efficient in the
absence of plasma because of the absence of plasma-
derived protease inhibitors; in our experiments, however,
binding occurred with IgG-preparations, but not when
plasma was present. Internalization is also not a con-
vincing explanation; in vivo and in the experiments with
whole blood ANCA, the PR3-expressing PMN coexist
with the plasma autoantibody. Thus, a continuous binding
of the autoantibody to PMN would be expected. By the
same argument, also clearance of autoantibody-coated
PMN is improbable, because neutropenia is not typically
seen during active disease. Blocking or shielding of the
PR3 binding sites could be possible, provided the block-
ing/shielding was selective for the autoantibody, and did
not inhibit the heterologous antibody. While we cannot
rule out this possibility, our data using purified IgG-PR3-
ANCA show that binding can be inhibited not only by
plasma but also by other sources of protein and by in-
creasing the reaction volume as well.
We propose the explanation that epitopes recognized
by the autoantibodies are not displayed by the surface-
associated PR3. Experiments with denatured PR3 as
antigen suggested a limited number of conformational
epitopes [33], while more recent studies, using peptides,
identified a restricted number of linear epitopes [34, 35].
It is possible that these epitopes are not accessible for the
autoantibody when PR3 is folded, or posttranslationally
modified or, as in the case of PR3 in vivo, is associated
with the cell surface. Already minor modifications of the
three-dimensional structure might be sufficient to reduce
the number of possible interactions between PR3 and
the autoantibody. When the epitope does not fit properly
into the antibody’s binding groove, low-affinity binding
ensues, which is readily perturbed by other proteins (e.g.,
plasma proteins) or when the reaction volume is large.
This, in turn, could explain why only purified IgG-PR3-
ANCA can bind, and not the IgG in plasma or in whole
blood. Heterologous antibodies (generated in rabbit or in
mice) with high affinity, in contrast, can bind even in the
presence of whole plasma or in larger reaction volumes.
That autoantibodies are of low affinity, compared to an-
tibodies obtained by immunization with a heterologous
protein, is in keeping with tolerance to self-antigens and
with the different route of antigen presentation.
At first glance, our data appear to contradict the wis-
dom accumulated over the years; at a second glance,
however, they concur with published data, though not
necessarily with the conclusions. First, our data are con-
sistent with the histomorphologic characterization of the
inflammatory lesions as “pauci immune,” a term coined
to describe the absence of immunoglobulins, but not of
cellular infiltrates, the latter being abundant. In patients
with glomerulonephritis, for example, in biopsies massive
infiltration of PMN was seen and also PR3, but no IgG, de-
spite high autoantibody titers [17]. To detect one without
the other is reminiscent of the data with peripheral blood
PMN of patients with active disease, and until proven dif-
ferently, the most reasonable explanation is that ANCA
do not bind to PMN in vivo.
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Another argument against binding of ANCA in vivo is
the observation that neutropenia is not typically seen in
Wegener’s granulomatosis, nor is a decrease of comple-
ment factors, which one would expect as result of comple-
ment activation by surface-bound IgG. As known from
true autoimmune diseases or from acquired neutrope-
nia, antibody-coated PMN are cleared rapidly from the
circulation [36]. One example for a presumed ANCA-
mediated neutropenia was described in a patient with
Graves’ disease, who, following treatment with propy-
lthiouracil, developed ANCAs. In this patient specific
binding to intact PMN of autoantibodies to PR3 and to
myeloperoxidase was described, which induced cytotox-
icity by an antibody- and complement-mediated process
[37]. Because of the different mode of autoantibody in-
duction, is it presumed that in this patient ANCA with
high affinity are generated, in contrast to the low-affinity
ANCA in patients with Wegener’s granulomatosis.
One of the major arguments for an involvement of
ANCA in the pathogenesis of vasculitis are the results re-
ported lately about an antibody to myeloperoxidase caus-
ing glomerulonephritis in a mouse strain [38]. It should be
emphasized that this study is concerned only with PR3-
ANCA and its link to Wegener’s granulomatosis and does
not address the issue of myeloperoxidase-ANCA or mi-
croscopic polyangiitis.
Another argument for a role of ANCA in Wegener’s
granulomatosis is its good correlation to disease activity.
Considering, however, that antibody de novo synthesis
requires expansion and differentiation of the respective
B-cell clones, it is quite feasible that autoantibodies occur
as a consequence of an inflammatory response, rather
than to create it.
Yet another argument for a role of ANCA in the patho-
genesis of Wegener’s granulomatosis is derived from
in vitro experiments describing activation of PMN by
ANCA. To the best of our knowledge and after extensive
review of the literature, the in vitro experiments were
carried out with IgG fractions of ANCA, with affinity-
purified antibodies, or with heterologous antibodies. That
IgG-ANCA or heterologous antibodies bind to PMN is
in agreement with our data, although in our hands bind-
ing was of low affinity, not entirely specific for PR3, and
did not occur with all IgG-ANCA preparations.
Nevertheless, that binding of IgG-ANCA to PMN ac-
tivates the cells is not debated here, nor do we have any
doubts that activated PMN are relevant effector cells
for the development of vasculitis or of kidney damage.
Moreover, we do not question the value of ANCA as
a diagnostic tool. Challenged here is the hypothesis that
PR3-ANCA are efficient activators of PMN in vivo, which
consequently sheds some doubt on the role of antibodies
to PR3 in the pathogenesis of Wegener’s granulomatosis,
at least as far as leukocyte activation in whole blood is
concerned.
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